An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

C. Haslund, A. Muhic, S. Lukacova, B. Lund, Y. Lassen-Ramshad, Mette Meyer, M. Roland, Hans Skovgaard Poulsen

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
JournalNeuro-Oncology
Volume18
Pages (from-to)iv6
Number of pages1
ISSN1522-8517
DOIs
Publication statusPublished - 1 Oct 2016
EventEANO 2016 Meeting - Mannheim, Germany
Duration: 12 Oct 201616 Oct 2016
Conference number: 12
https://www.eano.eu/eano2016/welcome/

Conference

ConferenceEANO 2016 Meeting
Number12
CountryGermany
CityMannheim
Period12/10/201616/10/2016
Internet address

Keywords

    Cite this

    @article{db7c450da8fd42dfb1f4d91530d7e1d5,
    title = "An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan",
    keywords = "Oncology, Neurosciences & Neurology",
    author = "C. Haslund and A. Muhic and S. Lukacova and B. Lund and Y. Lassen-Ramshad and Mette Meyer and M. Roland and Poulsen, {Hans Skovgaard}",
    year = "2016",
    month = "10",
    day = "1",
    doi = "10.1093/neuonc/now188.017",
    language = "English",
    volume = "18",
    pages = "iv6",
    journal = "Neuro-Oncology",
    issn = "1522-8517",
    publisher = "Oxford University Press",

    }

    An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan. / Haslund, C.; Muhic, A.; Lukacova, S.; Lund, B.; Lassen-Ramshad, Y.; Meyer, Mette; Roland, M.; Poulsen, Hans Skovgaard.

    In: Neuro-Oncology, Vol. 18, 01.10.2016, p. iv6.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

    TY - ABST

    T1 - An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

    AU - Haslund, C.

    AU - Muhic, A.

    AU - Lukacova, S.

    AU - Lund, B.

    AU - Lassen-Ramshad, Y.

    AU - Meyer, Mette

    AU - Roland, M.

    AU - Poulsen, Hans Skovgaard

    PY - 2016/10/1

    Y1 - 2016/10/1

    KW - Oncology

    KW - Neurosciences & Neurology

    U2 - 10.1093/neuonc/now188.017

    DO - 10.1093/neuonc/now188.017

    M3 - Conference abstract in journal

    VL - 18

    SP - iv6

    JO - Neuro-Oncology

    JF - Neuro-Oncology

    SN - 1522-8517

    ER -